Shares in 4SC AG dropped 36 percent June 8 on news that its orally available drug vidofludimus missed the primary endpoint of a Phase IIb trial in rheumatoid arthritis, dashing investor hopes of a near-term deal. (BioWorld International)
Shares in 4SC AG dropped 36 percent Wednesday on news that its orally available drug vidofludimus missed the primary endpoint of a Phase IIb clinical trial in rheumatoid arthritis, dashing investor hopes of a near-term deal.
BioInvent International AB topped its cash reserves by raising $22.1 million in a private placement directed at international institutional investors and certain Swedish investors.
The European Medicines Agency (EMA) has emulated the FDA in telling NeuroSearch A/S that it needs to conduct another Phase III trial of its Huntington's disease drug Huntexil (pridopidine, ACR16) before it can file for approval.
Evotec AG is missing out on a potential $65 million payday following its decision to terminate a Phase II trial of EVT.101 in treatment-resistant depression.
